EUVIMEDEUVIMED entdecken
Crossref

PEGylated liposomes co-encapsulating darolutamide and hesperetin for enhanced prostate cancer therapy: 2D, 3D PC3 models and in-vivo evaluation

Ruchita Patil, Ekta Pardhi, Rahul Khemchandani, Avinash Pawar, Gananadhamu Smanthula, Neelesh Kumar Mehra

Biomaterials Advances · 2026

DOI: 10.1016/j.bioadv.2025.214542 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biomaterials Advances, 2026. Verfasst von Ruchita Patil und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research, Hyderabad, Telangana, 500037, India. Hauptthemen laut MEDLINE: Liposomes, Hesperidin, Polyethylene Glycols, Prostatic Neoplasms. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 62 Literaturangaben. Gefördert von: National Institute of Pharmaceutical Education and Research, Ahmedabad, Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, India.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In this study, a darolutamide and hesperetin co-loaded PEGylated liposomal formulation (DHLP) was developed for the treatment of non-metastatic castration-resistant prostate cancer (nmCRPC). The formulation was prepared using the ethanol injection method, followed by membrane extrusion through a 100 nm polycarbonate filter to ensure size uniformity. The optimized DHLP liposomal formulation exhibited a clear bluish appearance, with a mean particle size of 106.5 ± 3.2 nm, a polydispersity index of 0.128 ± 0.023, and a zeta potential of -14.10 ± 0.25 mV, indicating colloidal stability and uniformity. Spherical morphology was confirmed through microscopic analysis. High encapsulation efficiencies were achieved for both DA (90.1 ± 3.3 %) and HE (91.3 ± 2.7 %). For both medication, in vitro drug release experiments showed a sustained release profile from the DHLP. Cytotoxicity assessment in PC3 prostate cancer cells revealed a 2.83-fold increase in cytotoxicity compared to free DA solution, a 3.89-fold increase compared to free HE solution, and a 1.47-fold improvement over the combined DA-HE solution. The combination index value of 0.89 confirmed synergistic anticancer activity. DHLPs inhibited cell migration, increased ROS generation, and reduced 3D spheroid size, with enhanced cellular uptake contributing to improved therapeutic efficacy. In-vivo pharmacokinetic studies in BALB/c mice demonstrated a 1.7- and 3.4-fold increase in the plasma half-life of DA and HE, respectively, compared to their free drug solutions. Biodistribution studies revealed reduced accumulation of DHLP in vital organs compared to the free drug solution. Acute toxicity assessment at three dose levels showed no histopathological alterations, indicating a favorable safety profile. These results imply that DHLP is a potential nanocarrier system for the effective management of prostate cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LiposomesHesperidinPolyethylene GlycolsProstatic NeoplasmsAntineoplastic AgentsMaleAnimalsHumansMicePC-3 CellsDrug LiberationCell Line, TumorParticle Size

Stichwörter der Autor:innen

DarolutamideHesperetinLiposomePEGylationPharmacokinetic

Substanzen

LiposomesHesperidinPolyethylene GlycolshesperetinAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research, Hyderabad, Telangana, 500037, India.
  • Department of Pharmaceutical Analysis, National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad, Telangana, 500037, India.
  • Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research, Hyderabad, Telangana, 500037, India. Electronic address: neelesh@niperhyd.ac.in.

Förderung

  • National Institute of Pharmaceutical Education and Research, Ahmedabad
  • Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, India

Zitieren

APA

Patil, R., Pardhi, E., Khemchandani, R., Pawar, A., Smanthula, G., & Mehra, N. K. (2026). PEGylated liposomes co-encapsulating darolutamide and hesperetin for enhanced prostate cancer therapy: 2D, 3D PC3 models and in-vivo evaluation. Biomaterials Advances. https://doi.org/10.1016/j.bioadv.2025.214542

Vancouver

Patil R, Pardhi E, Khemchandani R, Pawar A, Smanthula G, Mehra NK. PEGylated liposomes co-encapsulating darolutamide and hesperetin for enhanced prostate cancer therapy: 2D, 3D PC3 models and in-vivo evaluation. Biomaterials Advances. 2026. doi:10.1016/j.bioadv.2025.214542

BibTeX
@article{Patil2026,
  author = {Patil, Ruchita and Pardhi, Ekta and Khemchandani, Rahul and Pawar, Avinash and Smanthula, Gananadhamu and Mehra, Neelesh Kumar},
  title = {PEGylated liposomes co-encapsulating darolutamide and hesperetin for enhanced prostate cancer therapy: 2D, 3D PC3 models and in-vivo evaluation},
  journal = {Biomaterials Advances},
  year = {2026},
  doi = {10.1016/j.bioadv.2025.214542}
}
Kostenlos starten →